Medical Health & Life Science Research News

New report: Europe's procedure numbers for orthopedic biomaterials market research for 2017

Lack of reimbursements can limit the European orthopedic biomaterials market. When a product is reimbursed, it is more readily adopted.

- Advertising -

Europe Procedure Numbers for Orthopedic Biomaterials 2017 - MedPro is a new market research publication announced by Reportstack. 

General Report Contents
• Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
• Market Drivers & Limiters for each chapter segment
• Competitive Analysis for each chapter segment
• Section on recent mergers & acquisitions
Lack of reimbursements can limit the European orthopedic biomaterials market. When a product is reimbursed, it is more readily adopted.

For instance, in the hyaluronic acid market, most products are classified as medical devices and thus are not eligible for reimbursement.

- Advertising -

Only a few premium products under the umbrella of pharmaceuticals are reimbursed by the government or healthcare organizations.

In addition to not being as well received as reimbursed products, the lack of reimbursement drives pricing down in an effort to make them more affordable. This price deterioration will have a negative impact on the market, as it may not be economically feasible for certain competitors to penetrate a market with low ASPs.

Complete report available @ Europe Procedure Numbers for Orthopedic Biomaterials 2017 - MedPro

Unlike donated material, synthetic bone graft materials do not carry the risk of disease transmission, nor will they generate an immunogenic response in the recipient. As with allograft, the use of synthetic materials avoids the need for a second bone harvesting procedure.

These products have been steadily reducing the amount of autograft bone that doctors have been using. Popularity of synthetics due to the affordability and easy accessibility, synthetic products are becoming the preferred products over allografts, DBMs and autografts.

A wide range of synthetic products can offer flexibility and variety for different groups of patients. People in general are becoming more knowledgeable and accepting of synthetic products.

Scope
2013-2023

Companies Mentioned

Fidia Medtronic TRB Chemedica Meda Pharma Sanofi Genzyme Depuy Synthes Bioventus Laboratoire Genevrier Recordati Stryker RTI Biologics Croma-Pharma Zimmer Biomet Others include: Anika Therapeutics, Bioiberica, Documedica, Ferring, Geistlich, Integra Biologics, Kuros, LCA Pharma, Orotech, Plasmaconcept AG, Stella PharmaceuticalsAlphatec Spine

News From

Reportstack™ - Browse and Buy Market Research ReportsReportstack™
Category: Market Research Publishers and RetailersCompany profile: Reportstack is one of the largest online libraries of market research publications. At Reportstack, users can find top-level research products from the leading publishers at one place. The best in practice web technology implemented by Reportstack enhances overall user experience and changes the way people buy research reports online. The market coverage spans across multiple verticals including but not limited to: Pharma & Healthcare, Automotive & Transport, Manufacturing & Industry ...